Balyasny Asset Management LLC Nurix Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$4.25 - $10.71 $15,699 - $39,562	-3,694 Reduced 14.06%	22,581 $233,000
Q3 2023 Nov 14, 2023	BUY	$7.86 - $10.08 $206,521 - $264,852	26,275 New	26,275 $206,000
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $196,416 - $315,573	15,930 New	15,930 $208,000
Q3 2021 Nov 15, 2021	SELL	$22.71 - $36.69 $1.78 Million - $2.88 Million	-78,527 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$24.21 - $35.89 $849,093 - $1.26 Million	35,072 Added 80.71%	78,527 $2.08 Million
Q1 2021 May 17, 2021	BUY	$26.98 - $50.17 $1.17 Million - $2.18 Million	43,455 New	43,455 $1.35 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.